Growth hormone secretagogue: difference between revisions
Diff·revision 8 → 9·22:40, 26 Feb 2025
Difference between revision 8 and revision 9 of Growth hormone secretagogue. 6 lines changed; the page grew by 83 bytes.
| Revision 8 — 12:07, 2 Feb 2025 UnderfillUna (talk) alphabetise the see-also list 3,350 bytes +629 | Revision 9 — 22:40, 26 Feb 2025 KPV_Kester (talk) rm the aggregate purity claim — no source, and no such survey exists 3,433 bytes +83 | ||
|---|---|---|---|
| 31 | <ref name="molitch2011">Molitch ME, Clemmons DR, Malozowski S, et al. "Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline." ''Journal of Clinical Endocrinology and Metabolism'' 96(6):1587–1609 (2011). PMID 21602453.</ref> | 31 | <ref name="molitch2011">Molitch ME, Clemmons DR, Malozowski S, et al. "Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline." ''Journal of Clinical Endocrinology and Metabolism'' 96(6):1587–1609 (2011). PMID 21602453.</ref> |
| 32 | 32 | ||
| + | 33 | == See also == | |
| + | 34 | * [[Ipamorelin]] | |
| + | 35 | * [[CJC-1295]] | |
| + | 36 | * [[Sermorelin]] | |
| + | 37 | * [[Tesamorelin]] | |
| + | 38 | ||
| 33 | {{DEFAULTSORT:Growth hormone secretagogue}} | 39 | {{DEFAULTSORT:Growth hormone secretagogue}} |
| 34 | [[Category:Growth hormone secretagogues]] | 40 | [[Category:Growth hormone secretagogues]] |